Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spebrutinib - Celgene

Next Previous
X
Search
Drug Profile

Spebrutinib - Celgene

Alternative Names: AVL-292; CC-292

Latest Information Update: 29 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Acrylamides; Aniline compounds; Antineoplastics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • No development reported Cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)
  • 28 May 2021 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Late-stage disease, Second-line therapy or greater) in Austria (PO)
  • 28 May 2021 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top